UCSF Spinout Calithera Biosciences Takes $40 Million First Round
This article was originally published in The Pink Sheet Daily
The cancer-fighting drug researcher is developing methods of activating caspases, enzymes that induce programmed cell death.
You may also be interested in...
A five-year review of Series A financings finds no negative correlation between the size of an A round and the likelihood of an investor exit. Plus news on recent financings by Veracyte, Calithera Biosciences, Spark Therapeutics and Versant Ventures.
Third Rock launches a computation-heavy discovery firm aimed at natural products, with commitments worth up to $125 million in equity and other funding.
Sanofi has an option to acquire the start-up, which screens for drugs by studying the genomics of natural products – and its investors have an option to force a sale.